Cite
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma.
MLA
Tachiki, Lisa May Ling, et al. “Extended Duration of Treatment Using Reduced-Frequency Dosing of Anti-PD-1 Therapy in Patients with Advanced Melanoma and Merkel Cell Carcinoma.” Cancer Immunology, Immunotherapy, vol. 72, no. 11, Nov. 2023, pp. 3839–50. EBSCOhost, https://doi.org/10.1007/s00262-023-03539-8.
APA
Tachiki, L. M. L., Hippe, D. S., Williams Silva, K., Hall, E. T., McCamy, W., Fritzsche, D., Perdue, A., Majovski, J., Pulliam, T., Goldstein, D. A., Veatch, J., Ho, J., Nghiem, P. T., Thompson, J. A., & Bhatia, S. (2023). Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma. Cancer Immunology, Immunotherapy, 72(11), 3839–3850. https://doi.org/10.1007/s00262-023-03539-8
Chicago
Tachiki, Lisa May Ling, Daniel S. Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy, Dane Fritzsche, Andrea Perdue, et al. 2023. “Extended Duration of Treatment Using Reduced-Frequency Dosing of Anti-PD-1 Therapy in Patients with Advanced Melanoma and Merkel Cell Carcinoma.” Cancer Immunology, Immunotherapy 72 (11): 3839–50. doi:10.1007/s00262-023-03539-8.